AllSight
Companies · VTRS · Pharmaceutical Preparations

Viatris Inc (VTRS)

Viatris Inc (VTRS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Viatris Inc (VTRS) stock — financials & valuation

Key numbers for Viatris Inc (VTRS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 39/100 — a percentile rank of Viatris Inc’s fundamentals against Manufacturing peers, weakest on financial health. A quality ranking, not a price prediction.

Market cap$20.1B
P / S1.4×
EV / EBITDA11.2×
Gross margin34.8%
Operating margin-0.6%
Net margin-2.8%
Return on equity-2.9%
ROIC-0.2%
Revenue growth4.4%
Debt / equity0.9×
Dividend yield0.0%

Is Viatris Inc overvalued? P/S looks overvalued vs its 5-year range; EV/EBITDA looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Viatris Inc’s own financial statements and shown as context, never as advice.

Aug 6, 2026
Strong quarter lifts guidance, though Nashik disruptions cloud the second half
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact